Barclays PLC Sells 17,544 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Barclays PLC cut its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 9.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 168,768 shares of the company’s stock after selling 17,544 shares during the period. Barclays PLC owned approximately 0.22% of Travere Therapeutics worth $2,360,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. CWM LLC boosted its position in shares of Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares during the period. DRW Securities LLC bought a new stake in shares of Travere Therapeutics during the 2nd quarter worth approximately $95,000. Quarry LP purchased a new position in Travere Therapeutics during the 3rd quarter valued at $105,000. Forefront Analytics LLC grew its position in Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after acquiring an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in Travere Therapeutics in the second quarter worth $117,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TVTX shares. Leerink Partners reissued an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. HC Wainwright lowered their price objective on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Wedbush raised their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Piper Sandler boosted their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Finally, Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Insider Transactions at Travere Therapeutics

In other news, Director Jeffrey A. Meckler sold 40,000 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $14.06, for a total transaction of $562,400.00. Following the transaction, the director now owns 81,000 shares in the company, valued at $1,138,860. This represents a 33.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Sandra Calvin sold 12,090 shares of Travere Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00. Following the completion of the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $1,005,164.10. This trade represents a 18.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,090 shares of company stock valued at $1,372,847 in the last 90 days. Insiders own 4.06% of the company’s stock.

Travere Therapeutics Trading Down 0.1 %

Shares of NASDAQ:TVTX opened at $17.13 on Thursday. The company has a market capitalization of $1.34 billion, a PE ratio of -3.76 and a beta of 0.69. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.33. The business’s fifty day simple moving average is $18.13 and its 200-day simple moving average is $13.25.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. The company had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The firm’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.17) earnings per share. As a group, equities research analysts predict that Travere Therapeutics, Inc. will post -3.94 earnings per share for the current fiscal year.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.